{"mainPropery":{"diseaseId":7386,"diseaseName":"Philadelphia-negative chronic myeloid leukemia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7386/philadelphia-negative-chronic-myeloid-leukemia","synonyms":[],"synonyms-with-source":[],"identifiers":[]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":4012,"resourceName":"National CML Society","abbreviation":"","address1":"130 Inverness Plaza #307","address2":"","address3":"","address4":"","address5":"","city":"Birmingham","state":"AL","zip":"35242","country":"United States","phone":"","tty":"","tollFree":"1-877-431-2573","fax":"","email":"info@nationalcmlsociety.org","url":"https://www.nationalcmlsociety.org/","freeText":""}],"resource descriptions":[{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":614,"genericName":"Blinatumomab","tradeName":"Blincyto","tradeLink":"http://www.blincytorems.com/","manufacturer":"","sponsor":"Amgen, Inc.","indication":"March 2018 approval for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Previously approved in December 2014 for treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/blincyto","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614061.html"}],"EncodedName":"Philadelphia-negative_chronic_myeloid_leukemia"}